DK2258345T3 - Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor - Google Patents
Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor Download PDFInfo
- Publication number
- DK2258345T3 DK2258345T3 DK10181264.2T DK10181264T DK2258345T3 DK 2258345 T3 DK2258345 T3 DK 2258345T3 DK 10181264 T DK10181264 T DK 10181264T DK 2258345 T3 DK2258345 T3 DK 2258345T3
- Authority
- DK
- Denmark
- Prior art keywords
- dosage form
- solid
- weight
- surfactant
- hiv protease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (24)
1. Fast farmaceutisk doseringsform, der omfatter en fast dispersion af mindst en HIV-proteaseinhibitor i mindst én farmaceutisk acceptabel vandopløselig polymer og mindst et farmaceutisk acceptabelt overfladeaktivt middel, hvor doseringsformen omfatter ritonavir og et overfladeaktivt middel med en HLB-værdi på fra 4 til 10.
2. Fast doseringsform ifølge krav 1, hvor den faste dispersion omfatter en vandopløselig polymer med en Tg på mindst 50° C.
3. Fast doseringsform ifølge krav 1 eller 2, hvor den faste dispersion er en glasagtig opløsning eller en fast opløsning.
4. Fast doseringsform ifølge krav 1, hvor doseringsformen omfatter et farmaceutisk acceptabelt overfladeaktivt middel ud over det overfladeaktive middel med en HLB-værdi på fra 4 til 10.
5. Fast doseringsform ifølge krav 4, hvor det overfladeaktive middel, der har en HLB-værdi på fra 4 til 10, udgør mindst 50 vægt-% af den samlede mængde overfladeaktivt middel, der anvendes.
6. Fast doseringsform ifølge krav 1, hvor det overfladeaktive middel, der har en HLB-værdi på fra 4 til 10, er en sorbitanfedtsyreester.
7. Fast doseringsform ifølge krav 6, hvor det overfladeaktive middel, der har en HLB-værdi på fra 4 til 10, er valgt blandt sorbitanmonolaurat og sorbitan-monopalmitat.
8. Fast doseringsform ifølge krav 1, hvor doseringsformen omfatter, i forhold til doseringsformens vægt, fra 5 til 30 vægt-% af en HIV-proteaseinhibitor eller en kombination af HIV-proteaseinhibitorer, fra 50 til 85 vægt-% af en vandopløselig polymer eller en kombination af vandopløselige polymerer, fra 2 til 20 vægt-% af et overfladeaktivt middel eller en kombination af overfladeaktive midler og fra 0 til 15 vægt-% additiver.
9. Fast doseringsform ifølge krav 1, hvor den mindst ene HIV- proteaseinhibitor er en kombination af ritonavir og mindst en anden HIV-proteaseinhibitor, hvor doseringsformen udviser en doseringstilpasset AUC af ritonavirplasmakoncentration hos hunde på mindst 9 pg.h/ml/100 mg.
10. Fast doseringsform ifølge krav 2, hvor den mindst ene HIV- proteaseinhibitor er en kombination af ritonavir og lopinavir.
11. Fast doseringsform ifølge krav 1, hvor den faste dispersion omfatter en vandopløselig polymer med en Tg på fra 80 til 180° C.
12. Fast doseringsform ifølge krav 1, hvor doseringsformen omfatter en homopolymer eller copolymer af N-vinylpyrrolidon.
13. Fast doseringsform ifølge krav 1, hvor doseringsformen omfatter en copolymer af N-vinylpyrrolidon og vinylacetat.
14. Fast doseringsform ifølge krav 13, hvor doseringsformen omfatter en copolymer på 60 vægt-% af copolymeren, N-vinylpyrrolidon, og 40 vægt-% af copolymeren, vinylacetat.
15. Fast doseringsform ifølge krav 1, hvor doseringsformen indeholder mindst et additiv, der er valgt blandt strømningsregulatorer, sprængmidler, bulkmidler og smøremidler.
16. Fast doseringsform ifølge krav 1, hvor doseringsformen omfatter vandop-løselig(e) polymer(er), der er valgt blandt homopolymerer og copolymerer af N-vinyllactamer, celluloseestere og celluloseethere, højmolekylære polyalky-lenoxider, polyacrylater og polymethacrylater, polyacrylamider, vinylacetatpo-lymerer, delvist hydrolyseret polyvinylacetat, polyvinylalkohol, oligo- og po-lysaccharider og blandinger deraf.
17. Fast doseringsform ifølge krav 1, der kan opnås ved hjælp af en fremgangsmåde, der omfatter (i) at fremstille en homogen smelte af HIV-proteaseinhibitoren eller HIV-proteaseinhibitorerne, den eller de vandopløselige polymerer og det eller de overfaldeaktive midler, og (ii) at lade smelten stivne til opnåelse af et fast dispersionsprodukt.
18. Fast doseringsform ifølge krav 17, hvor et additiv, der er valgt blandt strømningsregulatorer, smøremidler, fyldstoffer, sprængmidler, blødgørere og stabilisatorer, er indbefattet i smelten.
19. Fast doseringsform ifølge krav 1, hvor den faste dispersion er en glasagtig opløsning eller en fast opløsning, der omfatter ritonavir og det overfladeaktive middel med en FILB-værdi på fra 4 til 10.
20. Fast doseringsform ifølge krav 1, hvor den faste dispersion er en glasagtig opløsning eller en fast opløsning, der omfatter ritonavir, en vandopløselig polymer med en Tg på mindst 50° C og det overfladeaktive middel med en HLB-værdi på fra 4 til 10.
21. Fast farmaceutisk doseringsform ifølge krav 1, omfattende en fast dispersion af ritonavir og lopinavir; en copolymer af N-vinylpyrrolidon og vinylacetat; og en sorbitanfedtsyreester.
22. Fast doseringsform ifølge krav 21, hvor doseringsformen indeholder mindst et additiv, der er valgt blandt strømningsregulatorer, sprængmidler, bulkmidler og smøremidler.
23. Fast farmaceutisk doseringsform ifølge krav 1, omfattende en fast dispersion af ritonavir og lopinavir, der forekommer i en mængde på fra 5 til 30 vægt-% af doseringsformen; en copolymer af N-vinylpyrrolidon og vinylacetat fra 50 til 85 vægt-% af doseringsformen; og en sorbitanfedtsyreester fra 2 til 20 vægt-% af doseringsformen.
24. Fast doseringsform ifølge et hvilket som helst af kravene 1 til 23 til anvendelse ved behandling af en HIV-infektion hos et pattedyr.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/650,178 US20050048112A1 (en) | 2003-08-28 | 2003-08-28 | Solid pharmaceutical dosage form |
| EP04816820A EP1663183B9 (en) | 2003-08-28 | 2004-08-23 | Solid pharmaceutical dosage form comprising ritonavir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2258345T3 true DK2258345T3 (da) | 2017-01-16 |
Family
ID=34217089
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04816820.7T DK1663183T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende ritonavir |
| DK10181250.1T DK2258344T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir |
| DK10181264.2T DK2258345T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor |
| DK10181268.3T DK2258346T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor |
| DK15169378.5T DK2942051T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04816820.7T DK1663183T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende ritonavir |
| DK10181250.1T DK2258344T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10181268.3T DK2258346T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor |
| DK15169378.5T DK2942051T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20050048112A1 (da) |
| EP (6) | EP2258345B1 (da) |
| JP (6) | JP4815348B2 (da) |
| KR (5) | KR101281994B1 (da) |
| CN (5) | CN1901884B (da) |
| AT (1) | ATE516017T1 (da) |
| AU (3) | AU2004283087C1 (da) |
| CA (2) | CA2536638C (da) |
| CR (3) | CR8256A (da) |
| CY (5) | CY1111981T1 (da) |
| DK (5) | DK1663183T3 (da) |
| EA (4) | EA020992B1 (da) |
| EC (1) | ECSP066397A (da) |
| ES (5) | ES2653762T3 (da) |
| HK (4) | HK1094766A1 (da) |
| HR (1) | HRP20110555T1 (da) |
| HU (3) | HUE035985T2 (da) |
| IL (3) | IL173939A (da) |
| ME (2) | MEP17608A (da) |
| MX (2) | MXPA06002346A (da) |
| NO (3) | NO330282B1 (da) |
| NZ (2) | NZ545499A (da) |
| PL (5) | PL2942051T3 (da) |
| PT (5) | PT2942051T (da) |
| RS (2) | RS59969B1 (da) |
| SG (3) | SG145690A1 (da) |
| SI (5) | SI2258344T1 (da) |
| TW (1) | TWI342221B (da) |
| UA (1) | UA85564C2 (da) |
| WO (1) | WO2005039551A2 (da) |
| ZA (3) | ZA200801362B (da) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1175205B1 (en) * | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
| US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| AU2012202831B2 (en) * | 2005-02-23 | 2015-01-22 | Abbvie Inc. | A solid pharmaceutical dosage formulation |
| KR20070025070A (ko) * | 2005-08-31 | 2007-03-08 | 주식회사 대웅제약 | 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법 |
| WO2007068615A2 (en) * | 2005-12-14 | 2007-06-21 | F. Hoffmann-La Roche Ag | Hcv prodrug formulation |
| RU2008128424A (ru) * | 2005-12-14 | 2010-01-20 | Сипла Лимитед (In) | Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы |
| WO2007087188A2 (en) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Taste-masked tablets and granules |
| EP1832281A1 (en) * | 2006-03-10 | 2007-09-12 | Abbott GmbH & Co. KG | Process for producing a solid dispersion of an active ingredient |
| EP1880715A1 (en) * | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| BRPI0714265A2 (pt) * | 2006-08-10 | 2013-04-16 | Cipla Ltd | composiÇço oral sàlida, processo para preparar uma composiÇço oral sàlida, uso de uma composiÇço e mÉtodo para tratar hiv |
| EP2112925A4 (en) * | 2006-11-15 | 2013-01-09 | Abbott Lab | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS |
| MX2009008935A (es) | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| GT200800303A (es) * | 2007-12-24 | 2009-09-18 | Combinacion anti-retroviral | |
| ES2607814T3 (es) * | 2008-02-28 | 2017-04-04 | Abbvie Inc. | Preparación de tabletas |
| WO2009153654A1 (en) * | 2008-06-17 | 2009-12-23 | Aurobindo Pharma Limited | Solid dosage forms of antiretrovirals |
| HUE030800T2 (en) * | 2008-10-07 | 2017-05-29 | Astrazeneca Uk Ltd | Pharmaceutical Form No. 514 |
| EP2391350A1 (en) | 2008-12-18 | 2011-12-07 | Ranbaxy Laboratories Limited | Atazanavir formulations |
| TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| TWI540132B (zh) | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| US20110034489A1 (en) | 2009-07-31 | 2011-02-10 | Ranbaxy Laboratories Limited | Solid dosage forms of hiv protease inhibitors |
| WO2011013110A1 (en) | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Unit dosage forms of hiv protease inhibitors |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| EP2683378A4 (en) * | 2011-03-07 | 2014-09-03 | Hetero Research Foundation | AMORPHOUS FORM OF A MIXTURE OF LOPINAVIR AND RITONAVIR |
| EP2714683A4 (en) | 2011-05-27 | 2014-11-05 | Hetero Research Foundation | RITONAVIR AMORPH CO-PRECIPITATION |
| EP2744481A4 (en) * | 2011-08-16 | 2015-07-01 | Merck Sharp & Dohme | USE OF INORGANIC MATRIX AND COMBINATIONS OF ORGANIC POLYMERS FOR THE PREPARATION OF STABLE AMORPHOUS DISPERSIONS |
| EP2564832A1 (en) | 2011-08-29 | 2013-03-06 | Hexal AG | Solid dosage form of HIV protease inhibitors |
| KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
| US9370578B2 (en) | 2012-03-07 | 2016-06-21 | Ratiopharm Gmbh | Dosage form comprising lopinavir and ritonavir |
| HUE027829T2 (en) | 2012-03-07 | 2016-11-28 | Ratiopharm Gmbh | Dosage forms containing non-crystalline lopinavir and crystalline ritonavir |
| CN103655571B (zh) * | 2012-09-11 | 2016-04-20 | 上海星泰医药科技有限公司 | 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法 |
| EP2900219B1 (en) | 2012-09-27 | 2016-07-06 | Basf Se | A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer |
| US9744240B2 (en) | 2012-09-27 | 2017-08-29 | Basf Se | Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer |
| JP6301339B2 (ja) | 2012-09-27 | 2018-03-28 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤 |
| US9789063B2 (en) | 2012-09-27 | 2017-10-17 | Basf Se | Storage-stable dust-free homogeneous particulate formulation |
| RU2505286C1 (ru) | 2012-12-29 | 2014-01-27 | Открытое Акционерное Общество "Фармасинтез" | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
| RU2543322C1 (ru) * | 2013-09-19 | 2015-02-27 | Открытое Акционерное Общество "Фармасинтез" | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
| RU2619840C1 (ru) * | 2016-09-21 | 2017-05-18 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция для лечения ВИЧ-инфекции |
| RU2659693C1 (ru) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции |
| US20190038754A1 (en) * | 2017-08-07 | 2019-02-07 | SE Tylose, USA, Inc. | Pharmaceutical composition in solid extruded form |
| WO2019166834A1 (en) * | 2018-03-02 | 2019-09-06 | The University Of Liverpool | Solid compositions of actives, processes for preparing same and uses of such solid compositions |
| CN108186578A (zh) * | 2018-03-27 | 2018-06-22 | 聊城大学 | 一种利托那韦固体分散体的制备方法 |
| EP3569225A1 (en) | 2018-05-18 | 2019-11-20 | Pharmaceutical Oriented Services Ltd | Solid dispersion containing ritonavir |
| TWI799599B (zh) * | 2019-06-06 | 2023-04-21 | 華納國際生物科技股份有限公司 | 醫藥或保健品自乳化固體分散組成物 |
| CN114146061B (zh) * | 2020-09-07 | 2023-06-30 | 歌礼生物科技（杭州）有限公司 | 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法 |
| CN113318076B (zh) * | 2021-06-02 | 2022-09-23 | 聊城大学 | 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法 |
| CN114557967B (zh) * | 2022-03-17 | 2023-06-02 | 乐普制药科技有限公司 | 一种利托那韦固体分散体的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2525108B1 (fr) | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
| DE3830353A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
| US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5542206A (en) | 1994-10-11 | 1996-08-06 | Lisch; Albert | Lure and tackle stacking container |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
| DE19841244A1 (de) * | 1998-09-09 | 2000-03-16 | Knoll Ag | Verfahren und Vorrichtung zum Herstellen von Tabletten |
| ES2307482T3 (es) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
| US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| DE19913692A1 (de) * | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| DE19913606A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen |
| MXPA01012478A (es) | 1999-06-04 | 2003-10-14 | Abbott Lab | Formulaciones farmaceuticas mejoradas. |
| EP1175205B1 (en) * | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
| EP1227797B1 (en) | 1999-11-12 | 2005-01-12 | Abbott Laboratories | Solid dispersion pharmaceutical formulations |
| CA2448864C (en) | 2001-06-22 | 2008-04-22 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
| ES2305434T3 (es) * | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
| DE10213242A1 (de) | 2002-03-25 | 2003-10-16 | Abbott Gmbh & Co Kg | Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren |
| DE10247037A1 (de) * | 2002-10-09 | 2004-04-22 | Abbott Gmbh & Co. Kg | Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| EP2112925A4 (en) | 2006-11-15 | 2013-01-09 | Abbott Lab | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS |
-
2003
- 2003-08-28 US US10/650,178 patent/US20050048112A1/en not_active Abandoned
-
2004
- 2004-08-23 KR KR1020117025014A patent/KR101281994B1/ko active IP Right Grant
- 2004-08-23 ES ES10181268.3T patent/ES2653762T3/es active Active
- 2004-08-23 ES ES04816820T patent/ES2367173T3/es active Active
- 2004-08-23 SI SI200431996T patent/SI2258344T1/sl unknown
- 2004-08-23 AT AT04816820T patent/ATE516017T1/de active
- 2004-08-23 WO PCT/US2004/027401 patent/WO2005039551A2/en active Application Filing
- 2004-08-23 EP EP10181264.2A patent/EP2258345B1/en not_active Revoked
- 2004-08-23 SG SG200805563-4A patent/SG145690A1/en unknown
- 2004-08-23 HU HUE10181268A patent/HUE035985T2/hu unknown
- 2004-08-23 KR KR20157009392A patent/KR20150044031A/ko not_active Application Discontinuation
- 2004-08-23 ZA ZA200801362A patent/ZA200801362B/en unknown
- 2004-08-23 EP EP15169378.5A patent/EP2942051B1/en active Active
- 2004-08-23 DK DK04816820.7T patent/DK1663183T3/da active
- 2004-08-23 PT PT151693785T patent/PT2942051T/pt unknown
- 2004-08-23 PT PT04816820T patent/PT1663183E/pt unknown
- 2004-08-23 RS RS20181262A patent/RS59969B1/sr unknown
- 2004-08-23 PL PL15169378T patent/PL2942051T3/pl unknown
- 2004-08-23 CA CA2536638A patent/CA2536638C/en not_active Expired - Fee Related
- 2004-08-23 JP JP2006524782A patent/JP4815348B2/ja active Active
- 2004-08-23 ES ES10181250T patent/ES2399810T3/es active Active
- 2004-08-23 UA UAA200603276A patent/UA85564C2/ru unknown
- 2004-08-23 SI SI200432367A patent/SI2258345T1/sl unknown
- 2004-08-23 ES ES15169378.5T patent/ES2666390T3/es active Active
- 2004-08-23 DK DK10181250.1T patent/DK2258344T3/da active
- 2004-08-23 ME MEP-176/08A patent/MEP17608A/xx unknown
- 2004-08-23 EP EP10181250A patent/EP2258344B1/en active Active
- 2004-08-23 ME MEP-2008-176A patent/ME00130B/me unknown
- 2004-08-23 KR KR1020127011945A patent/KR101457967B1/ko active IP Right Grant
- 2004-08-23 KR KR1020067004057A patent/KR101132602B1/ko active IP Right Grant
- 2004-08-23 NZ NZ545499A patent/NZ545499A/en not_active IP Right Cessation
- 2004-08-23 NZ NZ579622A patent/NZ579622A/en not_active IP Right Cessation
- 2004-08-23 DK DK10181264.2T patent/DK2258345T3/da active
- 2004-08-23 HU HUE10181264A patent/HUE031153T2/en unknown
- 2004-08-23 AU AU2004283087A patent/AU2004283087C1/en not_active Revoked
- 2004-08-23 MX MXPA06002346A patent/MXPA06002346A/es active IP Right Grant
- 2004-08-23 EA EA200900292A patent/EA020992B1/ru not_active IP Right Cessation
- 2004-08-23 PL PL10181264T patent/PL2258345T3/pl unknown
- 2004-08-23 SG SG2012008959A patent/SG179401A1/en unknown
- 2004-08-23 SI SI200432438T patent/SI2942051T1/en unknown
- 2004-08-23 PL PL10181268T patent/PL2258346T3/pl unknown
- 2004-08-23 MX MX2010013145A patent/MX358033B/es unknown
- 2004-08-23 EP EP10181268.3A patent/EP2258346B1/en not_active Revoked
- 2004-08-23 CA CA2689639A patent/CA2689639C/en not_active Expired - Fee Related
- 2004-08-23 DK DK10181268.3T patent/DK2258346T3/da active
- 2004-08-23 PT PT101812683T patent/PT2258346T/pt unknown
- 2004-08-23 EP EP17210362.4A patent/EP3354261A1/en not_active Withdrawn
- 2004-08-23 EA EA201890737A patent/EA201890737A3/ru unknown
- 2004-08-23 PL PL10181250T patent/PL2258344T3/pl unknown
- 2004-08-23 CN CN200480024748XA patent/CN1901884B/zh not_active Ceased
- 2004-08-23 PT PT101812501T patent/PT2258344E/pt unknown
- 2004-08-23 EP EP04816820A patent/EP1663183B9/en not_active Revoked
- 2004-08-23 DK DK15169378.5T patent/DK2942051T3/da active
- 2004-08-23 HU HUE15169378A patent/HUE038792T2/hu unknown
- 2004-08-23 EA EA200600473A patent/EA011924B1/ru not_active IP Right Cessation
- 2004-08-23 CN CN201210259721.5A patent/CN102772380B/zh not_active Ceased
- 2004-08-23 SI SI200432412T patent/SI2258346T1/sl unknown
- 2004-08-23 PL PL04816820T patent/PL1663183T3/pl unknown
- 2004-08-23 KR KR1020147007592A patent/KR101563222B1/ko active IP Right Grant
- 2004-08-23 SG SG10201507902UA patent/SG10201507902UA/en unknown
- 2004-08-23 CN CN201510531654.1A patent/CN105106104A/zh active Pending
- 2004-08-23 PT PT101812642T patent/PT2258345T/pt unknown
- 2004-08-23 CN CN2010102227346A patent/CN101919858B/zh not_active Ceased
- 2004-08-23 EA EA201301045A patent/EA033224B1/ru not_active IP Right Cessation
- 2004-08-23 ES ES10181264.2T patent/ES2608720T3/es active Active
- 2004-08-23 SI SI200431719T patent/SI1663183T1/sl unknown
- 2004-08-23 CN CN2012102597395A patent/CN102764244A/zh active Pending
- 2004-08-23 RS YU20060140A patent/RS57663B1/sr unknown
- 2004-08-27 TW TW093125927A patent/TWI342221B/zh active
-
2006
- 2006-02-23 CR CR8256A patent/CR8256A/es unknown
- 2006-02-24 EC EC2006006397A patent/ECSP066397A/es unknown
- 2006-02-26 IL IL173939A patent/IL173939A/en active IP Right Grant
- 2006-02-27 ZA ZA200601718A patent/ZA200601718B/xx unknown
- 2006-03-24 NO NO20061342A patent/NO330282B1/no not_active Application Discontinuation
- 2006-12-06 HK HK06113444.9A patent/HK1094766A1/xx not_active IP Right Cessation
-
2007
- 2007-12-19 AU AU2007249115A patent/AU2007249115B2/en not_active Revoked
-
2008
- 2008-02-08 ZA ZA2008/01361A patent/ZA200801361B/en unknown
-
2010
- 2010-03-15 NO NO20100367A patent/NO334418B1/no not_active Application Discontinuation
- 2010-07-27 IL IL207260A patent/IL207260A/en active IP Right Grant
- 2010-11-01 AU AU2010238573A patent/AU2010238573B2/en not_active Revoked
- 2010-12-30 HK HK10112283.9A patent/HK1145969A1/xx not_active IP Right Cessation
-
2011
- 2011-02-18 JP JP2011032972A patent/JP5498411B2/ja active Active
- 2011-07-06 JP JP2011149721A patent/JP5395125B2/ja active Active
- 2011-07-25 HR HR20110555T patent/HRP20110555T1/hr unknown
- 2011-09-22 CY CY20111100923T patent/CY1111981T1/el unknown
-
2012
- 2012-12-21 CR CR20120662A patent/CR20120662A/es unknown
- 2012-12-21 CR CR20120661A patent/CR20120661A/es unknown
-
2013
- 2013-02-01 CY CY20131100093T patent/CY1113596T1/el unknown
- 2013-08-13 JP JP2013168001A patent/JP5903413B2/ja active Active
- 2013-12-27 NO NO20131743A patent/NO335326B1/no not_active Application Discontinuation
-
2015
- 2015-12-04 JP JP2015237449A patent/JP2016094433A/ja not_active Withdrawn
-
2016
- 2016-05-10 HK HK16105307.9A patent/HK1217298A1/zh not_active IP Right Cessation
- 2016-12-19 CY CY20161101315T patent/CY1118505T1/el unknown
-
2017
- 2017-09-11 JP JP2017173733A patent/JP2018035163A/ja active Pending
- 2017-09-18 IL IL254581A patent/IL254581A0/en unknown
- 2017-11-03 CY CY20171101155T patent/CY1119651T1/el unknown
-
2018
- 2018-04-17 CY CY20181100407T patent/CY1120138T1/el unknown
- 2018-12-19 HK HK18116294.9A patent/HK1257502A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2258345T3 (da) | Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor | |
| US8399015B2 (en) | Solid pharmaceutical dosage form | |
| AU2013201423B2 (en) | Solid pharmaceutical dosage form |